GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Argos Therapeutics Inc (FRA:77AA) » Definitions » Institutional Ownership

Argos Therapeutics (FRA:77AA) Institutional Ownership : 1.08% (As of Jun. 12, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Argos Therapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Argos Therapeutics's institutional ownership is 1.08%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Argos Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Argos Therapeutics's Float Percentage Of Total Shares Outstanding is 63.99%.


Argos Therapeutics Institutional Ownership Historical Data

The historical data trend for Argos Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Argos Therapeutics Institutional Ownership Chart

Argos Therapeutics Historical Data

The historical data trend for Argos Therapeutics can be seen below:

2017-12-31 2018-03-31 2018-06-30
Institutional Ownership 0.11 1.10 1.08

Argos Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Argos Therapeutics (FRA:77AA) Business Description

Traded in Other Exchanges
N/A
Address
4233 Technology Drive, Durham, NC, USA, 27704
Argos Therapeutics Inc is a biopharmaceutical company. It is engaged in the development and commercialization of immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform called Arcelis.

Argos Therapeutics (FRA:77AA) Headlines

No Headlines